Raynaud's Disease Clinical Trial
Official title:
Phase II Dose Response Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, in the Treatment of Raynaud's Phenomenon
The Purpose of this study is to determine the response to two different strengths of a topical gel containing nitroglycerin in patients with Raynaud's disease.
The Purpose of this clinical study is to determine, in a controlled fashion, the response to two dosage strengths of a topical gel formulation of Nitroglycerin, MQX-503, in the determination of changes in finger blood flow and skin temperature in the fingers of patients with moderate to severe primary Raynaud's phenomenon and with Raynaud's phenomenon secondary to autoimmune diseases, such as scleroderma. The dosage strength response in the treatment of the symptoms (pain, tingling, numbness) will also be monitored. ;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00000530 -
Raynaud's Treatment Study (RTS)
|
Phase 3 | |
| Completed |
NCT00048763 -
Safety and Efficacy of Pletal(Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud’s Phenomenon
|
Phase 4 | |
| Completed |
NCT00048776 -
Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud’s Phenomenon
|
Phase 4 | |
| Enrolling by invitation |
NCT02615964 -
Nova Cold Hands Raynaud's Disorder, a Disease Which Results in Decreased Blood Flow to the Hands and Feet.
|
N/A | |
| Completed |
NCT01309802 -
A Two-Part Study of BOTOX® Therapy for Ischemic Digits
|
Phase 2 | |
| Completed |
NCT00480753 -
Dose Response Study of a Topical Formulation of Nitroglycerin for the Treatment of Raynaud's Phenomenon
|
Phase 2 | |
| Completed |
NCT02396238 -
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
|
N/A | |
| Completed |
NCT00351117 -
St. John's Wort in the Treatment of Raynaud's Phenomenon
|
Phase 3 | |
| Completed |
NCT00528242 -
Safety, Tolerability, and Pharmacodynamic Profile of Oral 2101 in Secondary Raynaud's Disease
|
Phase 2 | |
| Completed |
NCT02683408 -
Diosmiplex (Vasculera®) in Primary and Secondary Raynaud's Phenomenon
|
N/A | |
| Active, not recruiting |
NCT00577304 -
A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon
|
Phase 3 | |
| Completed |
NCT00419419 -
Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon
|
Phase 3 | |
| Completed |
NCT00266669 -
Phase III Study of Topical Gel for Treatment and Prevention of Raynaud's Phenomenon
|
Phase 3 | |
| Completed |
NCT01090492 -
PF-00489791 For The Treatment Of Raynaud's
|
Phase 2 |